UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q
(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                    For quarterly period ended March 31, 2010

                                       or

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

          For the transition period from _____________ to _____________

                        Commission File Number 000-53486


                              ENOX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)

           Nevada                                                26-0477124
(State or other jurisdiction of                               (I.R.S. employer
 incorporation or organization)                              identification no.)

                       303-1687 W. Broadway, Vancouver BC
                                 V6J 1X2 Canada
               (Address of principal executive offices)(Zip code)

                              Tel: + (604) 637-9744
                             Fax: +1 (888) 224-7259
              (Registrant's telephone number, including area code)

                                 Not Applicable
              (Former name, former address, and former fiscal year,
                         if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by checkmark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
definition of "large accelerated filer," "accelerated filer," and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]                        Accelerated filer [ ]
Non-accelerated filer [ ]                          Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The issuer has 12,829,587 shares of common stock outstanding as of May 17, 2010.
<PAGE>

                              ENOX BIOPHARMA, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          INDEX TO FINANCIAL STATEMENTS
                                 MARCH 31, 2010

                                                                            Page
                                                                            ----

Balance Sheets as of March 31, 2010 (Unaudited) and
December 31, 2009 (Audited)                                                  3

Statements of Operations for the Three Months Ended
March 31, 2010 and 2009, and from June 28, 2007 (inception)
to March 31, 2010 (Unaudited)                                                4

Statement of Stockholders' Equity from June 28, 2007 (inception)
to March 31, 2010 (Unaudited)                                                5

Statements of Cash Flows for the Three Months Ended
March 31, 2010 and 2009, and from June 28, 2007 (inception)
to March 31, 2010 (Unaudited)                                                6

Notes to the Financial Statements                                            7


                                       2
<PAGE>
                         PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

                              Enox Biopharma, Inc.
                          (A Development Stage Company)
                                 Balance Sheets

<TABLE>
<CAPTION>
                                                                      March 31, 2010       December 31, 2009
                                                                      --------------       -----------------
                                                                       (Unaudited)            (Audited)
<S>                                                                      <C>                  <C>
                                     ASSETS

CURRENT ASSETS:
  Cash                                                                   $ 151,526            $ 234,076
  Deposit                                                                    9,880                   --
  Prepaid expenses                                                          12,333               16,333
                                                                         ---------            ---------
TOTAL CURRENT ASSETS                                                       173,739              250,409

EQUIPMENT, NET                                                               1,001                1,143
                                                                         ---------            ---------

TOTAL ASSETS                                                             $ 174,740            $ 251,553
                                                                         =========            =========

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES:
  Accrued liability                                                      $  14,917            $      --
  Accounts payable                                                           1,820                1,400
                                                                         ---------            ---------
TOTAL CURRENT LIABILITIES                                                   16,737                1,400
                                                                         ---------            ---------

STOCKHOLDERS' EQUITY:
  Preferred stock, ($0.0001 par value, 50,000,000 shares authorized,
   no shares outstanding)                                                       --                   --
  Common stock, ($0.0001 par value, 100,000,000 shares authorized,
   12,829,587 and 12,829,587 issued and outstanding)                         1,283                1,283
  Additional paid in capital                                               960,379              844,898
  Deficit accumulated during the development stage                        (803,659)            (596,029)
                                                                         ---------            ---------
Total Stockholders' Equity                                                 158,003              250,152
                                                                         ---------            ---------

Total Liabilities and Stockholders' Equity                               $ 174,740            $ 251,552
                                                                         =========            =========
</TABLE>


                 See accompanying notes to financial statements

                                       3
<PAGE>
                              Enox Biopharma, Inc.
                          (A Development Stage Company)
                            Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                    June 28, 2007
                                                                                                   (Inception) to
                                                          For the three months Ended March 31,        March 31,
                                                              2010                   2009               2010
                                                          ------------           ------------       ------------
<S>                                                       <C>                    <C>                <C>
OPERATING EXPENSES:
  General and administrative expenses                     $    168,352           $     22,449       $    372,999
  Research and development                                      39,278                 19,167            430,660
                                                          ------------           ------------       ------------
TOTAL OPERATING EXPENSES                                       207,630                 41,616            803,659
                                                          ------------           ------------       ------------

NET LOSS                                                  $   (207,630)          $    (41,616)      $   (803,659)
                                                          ============           ============       ============

NET LOSS PER COMMON SHARE - BASIC AND DILUTED             $      (0.02)          $      (0.00)      $      (0.08)
                                                          ============           ============       ============

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
 DURING THE PERIOD - BASIC AND DILUTED                      12,829,587             11,199,417         10,487,373
                                                          ============           ============       ============
</TABLE>


                 See accompanying notes to financial statements

                                       4
<PAGE>
                              Enox Biopharma, Inc.
             Statement of Changes in Stockholders' Equity (Deficit)
             For the Years Ended December 31, 2009 and 2008 and from
                  June 28, 2007 (Inception) to March 31, 2010
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                         Common Stock,
                                                       $0.0001 Par Value      Additional                     Total
                                                      --------------------     Paid in     Accumulated    Stockholders'
                                                      Shares        Amount     Capital       Deficit         Equity
                                                      ------        ------     -------       -------         ------
<S>                                                  <C>            <C>       <C>           <C>            <C>
Common stock issued to founder and
 consultants for cash ($0.0001/share)                6,750,000      $  675    $      8      $      --      $     683

Common stock and warrants issued for
 cash ($0.06/share)                                  3,819,227         382     234,501             --        234,883

Net loss for the period from inception
 to December 31, 2007                                       --          --          --        (90,834)       (90,834)
                                                    ----------      ------    --------      ---------      ---------

Balance, December 31, 2007                          10,569,227       1,057     234,509        (90,834)       144,732

Common stock and warrants issued for
 cash ($0.25/share)                                    304,000          30      75,970             --         76,000

Common stock and warrants issued for
 cash ($0.30/share)                                    183,333          18      54,982             --         55,000

Common stock and warrants issued for
 cash ($0.35/share)                                    142,857          14      49,986             --         50,000

Options granted to consultant for services                  --          --      14,363             --         14,363

Net loss, 2008                                              --          --          --       (232,138)      (232,138)
                                                    ----------      ------    --------      ---------      ---------

Balance, December 31, 2008                          11,199,417       1,120     429,810       (322,972)       107,958

Common stock and warrants issued for
 cash ($0.30/share)                                    250,000          25      74,975             --         75,000

Common stock and warrants issued for
 cash ($0.35/share)                                     71,428           7      24,993             --         25,000

Common stock and warrants issued for
 cash ($0.45/share)                                    222,222          22      99,978             --        100,000

Warrants exercised for cash ($0.20/share)              893,663          89     178,643             --        178,732

Common stock issued in connection with
 cashless exercise of stock options                    192,857          19         (19)            --             --

Options granted to consultant for services                  --          --      36,519             --         36,519

Net loss, 2009                                              --          --          --       (273,057)      (273,057)
                                                    ----------      ------    --------      ---------      ---------

Balance, December 31, 2009                          12,829,587       1,283     844,898       (596,029)       250,152

Options granted to consultant for services
 rendered                                                   --          --     115,481             --        115,481

Net loss, 2010                                              --          --          --       (207,630)      (207,630)
                                                    ----------      ------    --------      ---------      ---------

BALANCE, MARCH  31, 2010                            12,829,587      $1,283    $960,379      $(803,659)     $ 158,003
                                                    ==========      ======    ========      =========      =========
</TABLE>
                 See accompanying notes to financial statements

                                       5
<PAGE>
                              Enox Biopharma, Inc.
                            Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                    June 28, 2007
                                                                                                   (Inception) to
                                                          For the three months Ended March 31,        March 31,
                                                              2010                   2009               2010
                                                           ----------             ----------         ----------
<S>                                                        <C>                    <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss                                                 $ (207,630)            $  (41,616)        $ (803,659)
  Adjustments to reconcile net loss to net
   cash used in operating activities:
     Depreciation                                                 142                    272             (1,001)
     Share based payment                                      115,481                     --            166,363
  Changes in operating assets and liabilities:
     Deposit                                                   (9,880)                    --             (9,880)
     Accrued Liability                                         14,917                 (9,525)            14,917
     Prepaid expenses                                           4,000                 (7,223)           (12,333)
     Accounts payable                                             420                    415              1,820
                                                           ----------             ----------         ----------
          NET CASH USED IN OPERATING ACTIVITIES               (82,551)               (57,677)          (643,774)
                                                           ----------             ----------         ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from issuance of common stock and warrants              --                     --            616,567
  Proceeds from exercise of warrants                               --                     --            178,732
  Proceeds from loan payable - related party                       --                     --                100
  Repayment of loan payable - related party                        --                     --               (100)
                                                           ----------             ----------         ----------
          NET CASH PROVIDED BY FINANCING ACTIVITIES                --                     --            795,299
                                                           ----------             ----------         ----------

NET INCREASE (DECREASE) IN CASH                               (82,551)               (57,677)           151,525

CASH - BEGINNING OF PERIOD                                    234,076                103,730                 --
                                                           ----------             ----------         ----------

CASH - END OF PERIOD                                       $  151,526             $   46,053         $  151,525
                                                           ==========             ==========         ==========

SUPPLEMENTARY CASH FLOW INFORMATION:

Cash paid during the period for:
  Income taxes                                             $       --             $       --         $       --
                                                           ==========             ==========         ==========
  Interest                                                 $       --             $       --         $       --
                                                           ==========             ==========         ==========
</TABLE>


                 See accompanying notes to financial statements

                                       6
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


NOTE 1 NATURE OF OPERATIONS

Enox  Biopharma,  Inc. (the "Company" or "Enox") was organized and  incorporated
under the laws of the State of Nevada on June 28, 2007.  The Company is focusing
on the development and  commercialization  of advanced Nitric Oxide technologies
for a variety  of medical  uses.  Enox's  patented  platform  technology  can be
utilized  across a wide spectrum of  applications  ranging from the treatment of
upper respiratory tract infections,  prevention of hospital acquired infections,
innovative  solutions  to assist in the  prevention  of the  common  cold and to
protect  people  from a diverse  array of life  threatening  and drug  resistant
infections.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

DEVELOPMENT STAGE

The Company's financial statements are presented as those of a development stage
enterprise.  Activities  during the development  stage primarily  include equity
based financing and further implementation of the business plan.

USE OF ESTIMATES

The  preparation of  consolidated  financial  statements in conformity with U.S.
generally accepted  accounting  principles requires management to make estimates
and assumptions that affect the amounts  reported in the consolidated  financial
statements and accompanying notes. Such estimates and assumptions impact,  among
others,  the  following:  the fair  value of options  granted  as  compensation,
estimates of the probability and potential  magnitude of contingent  liabilities
and the valuation allowance for deferred tax assets due to continuing  operating
losses.

Making estimates requires management to exercise significant  judgment. It is at
least  reasonably  possible  that the  estimate  of the  effect of a  condition,
situation or set of  circumstances  that existed at the date of the consolidated
financial  statements,  which management  considered in formulating its estimate
could  change  in the near  term due to one or more  future  confirming  events.
Accordingly, the actual results could differ significantly from our estimates.

RISKS AND UNCERTAINTIES

The  Company's  operations  are subject to  significant  risk and  uncertainties
including financial, operational,  technological, and regulatory risks including
the potential risk of business failure.  Also see Note 3 regarding going concern
matters.

RESEARCH AND DEVELOPMENT

Research and development is expensed as incurred.

                                       7
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


SHARE-BASED PAYMENTS

Generally,  all forms of share-based  payments,  including  stock option grants,
restricted stock grants and stock appreciation rights are measured at their fair
value on the awards' grant date,  based on the  estimated  number of awards that
are  ultimately  expected to vest.  Share-based  compensation  awards  issued to
non-employees for services rendered are recorded at either the fair value of the
services  rendered or the fair value of the  share-based  payment,  whichever is
more readily  determinable.  The expense resulting from share-based payments are
recorded  in cost of goods sold or  general  and  administrative  expense in the
consolidated  statement of  operations,  depending on the nature of the services
provided.

EARNINGS PER SHARE

In  accordance  with  accounting  guidance  now  codified as FASB ASC Topic 260,
"EARNINGS  PER SHARE," basic  earnings  (loss) per share is computed by dividing
net  income  (loss) by  weighted  average  number  of  shares  of  common  stock
outstanding during each period. Diluted earnings (loss) per share is computed by
dividing net income  (loss) by the weighted  average  number of shares of common
stock, common stock equivalents and potentially dilutive securities  outstanding
during the period.

RECENT ACCOUNTING PRONOUNCEMENTS

In  January  2010,  the  Financial  Accounting  Standards  Board  (FASB)  issued
Accounting Standards Update No. 2010-06, "IMPROVING DISCLOSURES ABOUT FAIR VALUE
MEASUREMENTS   ("ASU  2010-06").   ASU  2010-06  amends  ASC  820,  "FAIR  VALUE
MEASUREMENTS"  ("ASC  820")  to  require  a  number  of  additional  disclosures
regarding fair value  measurements.  The amended guidance  requires  entities to
disclose the amounts of significant transfers between Level 1 and Level 2 of the
fair value  hierarchy and the reasons for these  transfers,  the reasons for any
transfers  in or out of  Level  3,  and  information  in the  reconciliation  of
recurring Level 3 measurements about purchases, sales, issuances and settlements
on a gross  basis.  The ASU also  clarifies  the  requirement  for  entities  to
disclose  information  about both the  valuation  techniques  and inputs used in
estimating Level 2 and Level 3 fair value measurements. The amended guidance was
effective for financial  periods  beginning after December 15, 2009,  except the
requirement  to disclose Level 3  transactions  on a gross basis,  which becomes
effective for financial  periods  beginning after December 15, 2010. ASU 2010-06
did not  have a  significant  effect  on the  Company's  consolidated  financial
position or results of operations.

                                       8
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


NOTE 3 GOING CONCERN

As reflected in the  accompanying  financial  statements,  the Company has a net
loss of $207,630 and net cash used in operations of $82,551 for the period ended
March 31, 2010.  The Company is in the  development  stage and has not generated
any revenues.

The  ability  of  the  Company  to  continue  its  operations  is  dependent  on
Management's  plans,  which  include the raising of capital  through debt and/or
equity markets with some  additional  funding from other  traditional  financing
sources, including term notes, until such time that funds provided by operations
are  sufficient to fund working  capital  requirements.  The Company may need to
incur  additional  liabilities  with  certain  related  parties to  sustain  the
Company's existence.

The Company will require additional funding to finance the growth of its current
and expected future  operations as well as to achieve its strategic  objectives.
The Company believes its current available cash along with anticipated  revenues
may be insufficient to meet its cash needs for the near future.  There can be no
assurance that financing will be available in amounts or terms acceptable to the
Company, if at all.

The  accompanying  financial  statements  have been  prepared on a going concern
basis,  which  contemplates  the  realization of assets and the  satisfaction of
liabilities in the normal course of business.  These financial statements do not
include any  adjustments  relating to the recovery of the recorded assets or the
classification  of the liabilities that might be necessary should the Company be
unable to continue as a going concern.

NOTE 4 LOANS PAYABLE RELATED PARTY

In 2007, the Company's  Chief Executive  Officer  advanced $100. The advance was
non-interest bearing, unsecured and due on demand. The $100 was repaid in 2008.

NOTE 5 STOCKHOLDERS EQUITY

I. FOUNDER SHARES, COMMON STOCK AND WARRANTS

FOR THE YEAR ENDED DECEMBER 31, 2007

On June 28, 2007  (inception),  the Company  issued  6,350,000  shares of common
stock to founders and 400,000 shares of common stock to consultants  for a total
of $683 ($0.0001/share).

During 2007, the Company had the following private placement:

DECEMBER 28, 2007

*    3,819,227 units for $234,883 ($0.06/unit),
*    Each unit  consisted  of one  share of stock  (3,819,227)  and one  warrant
     (3,819,227 Series "A"),
*    Series "A" warrants have an exercise price of $0.20/share and an expiration
     date of two years, FOR THE YEAR ENDED DECEMBER 31, 2008

                                       9
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


During 2008, the Company had the following private placements:

(A) JULY 15, 2008

*    304,000 units for $76,000 (0.25/unit),
*    Each  unit  consisted  of one  share of stock  (304,000)  and two  warrants
     (304,000 Series "A") and (304,000 Series "B"),
*    Series "A" warrants have an exercise price of $0.30/share and an expiration
     date of one year,
*    Series "B" warrants have an exercise price of $0.40/share and an expiration
     date of two years.

(B) JULY 20, 2008

*    183,000 units for $55,000 ($0.30/unit),
*    Each  unit  consisted  of one  share of stock  (183,333)  and two  warrants
     (183,333 Series "A") and (183,333 Series "B"),
*    Series "A" warrants have an exercise price of $0.35/share and an expiration
     date of one year,
*    Series "B" warrants have an exercise price of $0.45/share and an expiration
     date of two years.

(C) DECEMBER 25, 2008

*    142,857 units for $50,000 ($0.35/unit),
*    Each  unit  consisted  of one  share of  stock  (142,857)  and one  warrant
     (142,857 Series "A"),
*    Series "A" warrants have an exercise price of $0.20/share and an expiration
     date of three years.

FOR THE YEAR ENDED DECEMBER 31, 2009

During 2009, the Company had the following private placements:

(A) JULY 2, 2009

*    14,285 units for $5,000 ($0.35/unit),
*    Each unit consisted of one share of stock (14,285) and one warrant  (14,285
     Series "A"),
*    Series "A" warrants have an exercise price of $0.50/share and an expiration
     date of three years.

(B) JULY 22, 2009

*    57,143 units for $20,000 ($0.35/share)

                                       10
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


(C) JULY 28, 2009

*    250,000 units for $75,000 ($0.30/unit),
*    Each  unit  consisted  of one  share of  stock  (250,000)  and one  warrant
     (250,000 Series "A"),
*    Series "A" warrants have an exercise price of $0.40/share and an expiration
     date of two years.

(D) NOVEMBER 23, 2009

*    111,111 units for $100,000 ($0.90/unit),
*    Each unit  consisted  of two  shares  of stock  (222,000)  and one  warrant
     (111,000 Series "A"),
*    Series "A" warrants have an exercise price of $0.60/share and an expiration
     date of two years.

(E) DURING 2009, THE COMPANY HAD THE FOLLOWING WARRANT EXERCISES:

*    July 10, 2009 - 50,000 shares at $0.20/share for $10,000.
*    November 12, 2009 - 250,000 shares at $0.20/share for $50,000.
*    December 28, 2009 - 593,663 shares at $0.20/share for $118,732

The following is a summary of the Company's  warrants that are  outstanding  and
exercisable at March 31, 2010, December 31, 2009 and 2008:

<TABLE>
<CAPTION>
                                                                              Weighted
                                                                              Average
                                                                Weighted      Remaining
                                                                 Average     Contractual
                                                                Exercise      Life in      Intrinsic
                                                 Warrants        Price         Years         Value
                                                 --------        -----         -----         -----
<S>                                            <C>               <C>           <C>        <C>
Balance - December 31, 2008                      4,986,750        0.23          0.54
Granted                                            375,396        0.46
Exercised                                       (3,462,897)         --
Forfeited/Cancelled                               (893,663)         --
                                               -----------       -----
Balance - December 31, 2008 - outstanding        1,005,586        0.40          1.18         $   --
                                               ===========       =====         =====
Balance - December 31, 2008 - exercisable        1,005,586        0.40          1.18         $   --
                                               ===========       =====         =====
Granted                                                 --          --
Exercised                                               --          --
Forfeited/Cancelled                                     --          --
                                               -----------       -----
Balance - March 31, 2010 - outstanding           1,005,586        0.40          0.93         $   --
                                               ===========       =====         =====
Balance - March 31, 2010  - exercisable          1,005,586        0.40          0.93         $   --
                                               ===========       =====         =====
</TABLE>

                                       11
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


II. STOCK OPTIONS

(A) STOCK OPTION GRANT IN 2008

On December 20, 2008,  the Company  granted  100,000 stock options having a fair
value of $14,363 for services rendered.

(B) STOCK OPTION GRANT AND EXERCISE IN 2009

On September 25, 2009, the Company  granted  350,000 stock options having a fair
value of $36,519 for services rendered.

On September  25, 2009,  the Company  issued  192,857  shares of common stock in
connection  with a cashless  exercise  provision  related to all  450,000  stock
options previously granted.

(C) STOCK OPTION GRANT IN 2010

During the three  months  ended March 31, 2010,  the Company  granted  3,886,938
stock  options,  having a grant date fair value of  $1,604,607,  and  recognized
$115,481 of expense associated with these share based payments as follows:

On January 1, 2010,  the Company  granted  800,000 stock options  having a grant
date fair value of $328,521,  which vest evenly over a thirty six month  period,
for services rendered.

On January 9, 2010, the Company  granted  1,886,938 stock options having a grant
date fair value of $783,702,  which vest evenly over a thirty six month  period,
for services rendered.

On February 1, 2010,  the Company  granted  200,000 stock options having a grant
date fair value of $82,069,  which vest over a two year  period,  quarterly,  at
50,000 shares  beginning  August 1, 2010 through  February 1, 2012, for services
rendered.

On February 15, 2010, the Company granted 1,000,000 stock options having a grant
date fair value of $410,315,  which vest evenly over a thirty six month  period,
for services rendered.

The Company determined the fair value of its share based payments based upon the
following assumptions:

                                        2010          2009           2008
                                        ----          ----           ----
     Expected term                        5 years       2 years         2 years
     Expected volatility                150%          100%            100%
     Expected dividends                   0%            0%              0%
     Risk free interest rate      2.35-2.69%         0.30%           0.30%
     Expected forfeitures                 0%            0%              0%

                                       12
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                 March 31, 2010
                                   (Unaudited)


The following is a summary of the  Company's  options that are  outstanding  and
exercisable at March 31, 2010, December 31, 2009 and 2008:

<TABLE>
<CAPTION>
                                                                              Weighted
                                                                              Average
                                                                Weighted      Remaining
                                                                 Average     Contractual
                                                                Exercise      Life in      Intrinsic
                                                 Options         Price         Years         Value
                                                 -------         -----         -----         -----
<S>                                            <C>               <C>           <C>        <C>
Balance - December 31, 2008
Granted                                           100,000         0.20
Exercised                                         350,000         0.20
Forfeited/Cancelled                              (450,000)        0.20
                                               ----------        -----
Balance - December 31, 2009 - outstanding              --           --              --       $  --
                                               ==========        =====      ==========
Balance - December 31, 2009 - exercisable              --           --              --       $  --
                                               ==========        =====      ==========
Granted                                         3,886,938         0.40
Exercised                                              --           --
Forfeited/Cancelled                                    --           --
                                               ----------        -----
Balance - March 31, 2010 - outstanding          3,886,938         0.40      4.80 years       $  --
                                               ==========        =====      ==========
Balance - March 31, 2010 - exercisable            279,467         0.39      4.79 years       $  --
                                               ==========        =====      ==========
</TABLE>

NOTE 6 COMMITMENTS AND CONTINGENCIES

(A) LITIGATIONS, CLAIMS AND ASSESSMENTS

From time to time, the Company may become involved in various lawsuits and legal
proceedings, which arise in the ordinary course of business. However, litigation
is subject to inherent  uncertainties,  and an adverse  result in these or other
matters may arise from time to time that may harm its  business.  The Company is
currently  not aware of any such legal  proceedings  or claims that they believe
will have,  individually or in the aggregate,  a material  adverse affect on its
business, financial condition or operating results.

(B) EMPLOYMENT AGREEMENTS AND CONSULTING AGREEMENTS

In 2010, the Company entered into agreements with  individuals who will serve as
officers and directors. The terms of these agreements are as follows:

     1.   Chief Executive Officer (January 1, 2010)
          a.   Monthly fee of $6,000.
          b.   800,000 stock options having a grant date fair value of $328,521,
               which vest evenly over a thirty six month period.

                                       13
<PAGE>
     2.   Chairman (January 9, 2010)
          a.   Entitled to receive  monthly cash payment based upon Company's on
               hand  cash  resources.  Currently,  the  Company  does  not  have
               sufficient resources to meet the agreed upon amounts.
          b.   1,886,938  stock  options  having  a grant  date  fair  value  of
               $783,702, which vest evenly over a thirty six month period.

     3.   Consultant (February 1, 2010)

          a.   Annual salary - $50,000
          b.   200,000 stock options  having a grant date fair value of $82,069,
               which vest over a two year period,  quarterly,  at 50,000  shares
               beginning August 1, 2010 through February 1, 2012.

     4.   Chief Financial Officer (February 15, 2010)
          a.   1,000,000  stock  options  having  a grant  date  fair  value  of
               $410,315, which vest evenly over a thirty six month period.

     5.   Investor Relations & Public Relations (March 15, 2010)
          a.   Monthly retainer of $8,000. Under the agreement until the company
               has  raised  capital in the  amount of at least  $3,000,000,  the
               company shall pay $2,500 per month,  whereas the remaining $5,500
               per month shall be deferred  until the  Investment  Threshold  is
               reached.

NOTE 7 SUBSEQUENT EVENTS

On April 30, 2010, the Company granted 200,000 warrants to acquire  intellectual
property from two  individuals.  These warrants have an exercise price of $1.00,
and expire in 2 years. The fair of these warrants is $52,960.  The warrants vest
immediately.

The Company  determined  the fair value of these share based payments based upon
the following assumptions:

     Expected term                      2 years
     Expected volatility              150%
     Expected dividends                 0%
     Risk free interest rate         0.97%
     Expected forfeitures               0%


                                       14
<PAGE>
ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

FORWARD LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements.
Forward-looking statements may include our statements regarding our goals,
beliefs, strategies, objectives, plans, including product and service
developments, future financial conditions, results or projections or current
expectations. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential" or "continue," the negative of
such terms, or other comparable terminology. Such forward-looking statements
appear in this Item 2 - "Management's Discussion and Analysis of Financial
Condition and Results of Operations," and include statements regarding our
expectations regarding our short - and long-term capital requirements and our
business plan and estimated expenses for the coming 12 months. These statements
are subject to known and unknown risks, uncertainties, assumptions and other
factors that may cause actual results to be materially different from those
contemplated by the forward-looking statements. The business and operations of
Enox Biopharma, Inc. are subject to substantial risks, which increase the
uncertainty inherent in the forward-looking statements contained in this report.
We undertake no obligation to release publicly the result of any revision to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. Further information on potential factors that could affect
our business is described under the heading "Risks Related To Our Business,
Strategy, And Industry" in Part I, Item 1, "Risk Factors" in our registration
statement on Form S-1 no 333-154763, which was declared effective on October 31,
2008. Readers are also urged to carefully review and consider the various
disclosures we have made in this report.

OVERVIEW

Enox Biopharma, Inc. ("Enox", "us", "we" and "our") was incorporated on June 28,
2007 in the State of Nevada. We are a development stage biotechnology company,
and to date have not earned any revenue and currently do not have any
significant assets. Our corporate offices are located at 303-1687 W. Broadway,
Vancouver BC, V6J 1X2, Canada. Our telephone number is (604) 637-9744 and our
fax number is (888) 224-7259. We do not have any subsidiaries. We have a website
at www.enoxbiopharma.com, however, the information contained on our website does
not form part of this Quarterly Report.

We are focusing on the development and commercialization of advanced Nitric
Oxide technologies for a variety of medical uses. Enox's patented platform
technology can be utilized across a wide spectrum of applications ranging from
the treatment of upper respiratory tract infections, prevention of hospital
acquired infections (HAI), innovative solutions to assist in the prevention of
the common cold and to protect people from a diverse array of life threatening,
drug resistant, infections.

Our technology and intellectual property is currently secured by one issued U.S
patent application, two US provisional applications and one US utility patent
application which we filed with the US Patent and Trademark Office.

During the fiscal period ending March 31, 2010 we expanded our IP portfolio by
licensing additional patents and we have began negotiating with various
institutions to secure new technology licensing. We believe that our
diversification into a broader nitric oxide based IP will provide us with a
strong foundation to develop new global business opportunities. We have
increased the scope and depth of our board of directors by appointing Mr. Amir
Avniel as our Chairman of the Board and grown our business team by hiring a
business development manager.

RESULTS OF OPERATIONS - THREE MONTHS ENDED MARCH 31, 2010 COMPARED TO THE THREE
MONTHS ENDED MARCH 31, 2009

During the three months ended March 31, 2010, we incurred operating expenses of
$207,630, an increase of $166,014 or approximately 25% from the three month
ended March 31, 2010. Operating expenses increased during the three month ended
March 31, 2010 from the comparative period due to issuing options of the
consultant. Other significant elements include:

                                       15
<PAGE>
     *    research and development costs of $39,278, which increased from
          $19,167 during the same period in the prior year, an increase of
          approximately 105%, due to prepaid expenses and accrued liabilities
          for research and development;
     *    general and administrative fees of $168,352, which is an increase from
          $22,449 during the same period in the prior year, an increase of
          approximately 650%, due to increase in consulting, professional fess
          related to accounting and legal services, increase in travel and other
          related expenses;

NET LOSS

We incurred a net loss of $207,630 for the three months ended March 31, 2010,
compared to a net loss of $41,616 for the three months ended March 31, 2009.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have had negative cash flows from operations and we have been
dependent on sales of our equity securities to meet our cash requirements. We
expect this situation to continue for the foreseeable future. We anticipate that
we will have negative cash flows from operations in the next twelve month
period.

As of March 31, 2010, we had cash of $151,526, representing a net increase in
cash of $82,551 since December 31, 2009.

There was no cash generated by financing activities during the three months
ended March 31, 2010. Cash used in operating activities amounted to $82,551
represented by a loss of $207,630 plus an increase in prepaid expenses from the
previous balance sheet of $4,000, common stock based compensation of $115,481 ,
depreciation and amortizing of $142, offset by accounts payable of $420 and
accrued liabilities of $14,917 .

Because we have not generated any revenue from our business, we will need to
raise additional funds for the future development of our business and to respond
to unanticipated requirements or expenses. We believe our current cash balances
will be extinguished by the fourth quarter of 2010, provided we do not have any
unanticipated expenses. We do not currently have any arrangements for financing
and we can provide no assurance to investors we will be able to find such
financing. There can be no assurance that additional financing will be available
to us, or on terms that are acceptable. Consequently, we may not be able to
proceed with our intended business plans or complete the development and
commercialization of our product.

If we fail to generate sufficient net revenues, we will need to raise additional
capital to continue our operations thereafter. We cannot guarantee that
additional funding will be available on favorable terms, if at all. Any
shortfall will effect our ability to expand or even continue our operations. We
cannot guarantee that additional funding will be available on favorable terms,
if at all.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4/4T. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

As required by Rule 13a-15/15d-15 under the Securities and Exchange Act of 1934,
as amended (the "Exchange Act"), as of March 31, 2010, we have carried out an
evaluation of the effectiveness of the design and operation of our Company's
disclosure controls and procedures. This evaluation was carried out under the
supervision and with the participation of our Company's management, our
President (Principal Executive Officer) and Treasurer (Principal Accounting
Officer). Based upon the results of that evaluation, our management has
concluded that, as of March 31, 2010, our Company's disclosure controls and
procedures were effective and provide reasonable assurance that material
information related to our Company required to be disclosed in the reports that
we file or submit under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the SEC's rules and forms, and
that such information is accumulated and communicated to management to allow
timely decisions on required disclosure.

                                       16
<PAGE>
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is responsible for establishing and maintaining adequate internal
control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f)
under the Exchange Act. Our internal control system is designed to provide
reasonable assurance to our management and board of directors regarding the
reliability of financial reporting and the preparation of financial statements
for external reporting purposes in accordance with generally accepted accounting
principles. Our internal control over financial reporting includes those
policies and procedures that:

     *    Pertain to the maintenance of records that, in reasonable detail,
          accurately and fairly reflect the transactions and dispositions of the
          assets of the Company;
     *    Provide reasonable assurance that transactions are recorded as
          necessary to permit preparation of financial statements in accordance
          with generally accepted accounting principles in the United States of
          America, and that receipts and expenditures of the Company are being
          made only in accordance with authorizations of management and
          directors of the Company; and
     *    Provide reasonable assurance regarding prevention or timely detection
          of unauthorized acquisition, use or disposition of the Company's
          assets that could have a material effect on the financial statements.

Management assessed the effectiveness of our internal control over financial
reporting as of March 31, 2010. In making this assessment, we used the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO) in Internal Control -- Integrated Framework.

Because of the material weaknesses described below, our management, under the
supervision of and with the participation of our Chief Executive Officer and
Chief Financial Officer, concluded that, as of March 31, 2010, our internal
control over financial reporting was not effective based on the criteria in
Internal Control -- Integrated Framework issued by the COSO.

A material weakness is a deficiency, or combination of deficiencies, in internal
control over financial reporting such that there is a reasonable possibility
that a material misstatement of our annual or interim consolidated financial
statements will not be prevented or detected on a timely basis.

In our assessment of the effectiveness of internal control over financial
reporting as of March 31, 2010, we identified that our material weaknesses
derived from the small size of our Company. That small size makes the proper
identification and authorization of transactions difficult, as we have
essentially only two individuals overseeing this process, which and creates
difficulties with separation of duties for handling, approving and coding
invoices, entering transactions into the accounts, writing checks and requests
for wire transfers. Additionally, the Company's officers are also its sole board
members. This does not provide an adequate level of layers of internal controls,
which in turn make it difficult to accumulate information required to be
disclosed by our Company in the reports that it files or submits under the
Exchange Act.

This annual report does not include an attestation report of the Company's
independent registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
Company's independent registered public accounting firm pursuant to temporary
rules of the SEC that permit the Company to provide only management's report in
this annual report.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes in our internal control over financial reporting
identified in connection with the evaluation described above during the quarter
ended March 31, 2010 that has materially affected or is reasonably likely to
materially affect our internal controls over financial reporting.

                                       17
<PAGE>
                           PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS

(a) Pursuant to Rule 601 of Regulation SK, the following exhibits are included
herein or incorporated by reference.

Exhibit
Number                               Description
------                               -----------

10.1      Assignment of Patent Agreement dated April 30, 2010 between Enox
          Biopharma, Inc and Dr. Jon Lundberg, Dr. Eddie Weitzberg and
          Nitricare, HB (incorporated herein by reference to Exhibit 10.1 of the
          Company's Current Report on Form 8-K filed May 6, 2010

31.1      Certification of CEO Pursuant to 18 U.S.C. ss. 1350, Section 302

31.2      Certification of CFO Pursuant to 18 U.S.C. ss. 1350, Section 302

32.1      Certification Pursuant to 18 U.S.C. ss.1350, Section 906

32.2      Certification Pursuant to 18 U.S.C. ss. 1350, Section 906

                                       18
<PAGE>
                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

Enox Biopharma, Inc.

By: /s/ Prof. Yossef Av-Gay
   --------------------------------------------
   Prof. Yossef Av-Gay, Chief Executive Officer
   (Principal Executive Officer)
   Dated: May 17, 2010


By: /s/ Itamar David
   --------------------------------------------
   Mr. Itamar David, Chief Financial Officer
   (Principal Financial and Accounting Officer)
   Dated: May 17, 2010

Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.


By: /s/ Prof. Yossef Av-Gay
   --------------------------------------------
   Prof. Yossef Av-Gay, Chief Executive Officer
   (Principal Executive Officer)
   Dated: May 17, 2010


By: /s/ Itamar David
   --------------------------------------------
   Mr. Itamar David, Chief Financial Officer
   (Principal Financial and Accounting Officer)
   Dated: May 17, 2010


By: /s/ Amir Avniel
   --------------------------------------------
   Mr. Amir Avniel, Chairman of the Board of
   Directors
   Dated: May 17, 2010


                                       19